Cipher Pharmaceuticals

217 articles with Cipher Pharmaceuticals

• Cipher Pharmaceuticals Announces Automatic Repurchase Plan Pursuant to its Normal Course Issuer Bid

  3/25/2021

  Cipher Pharmaceuticals Inc. announced that it has received approval from the Toronto Stock Exchange to amend its normal course issuer bid in order to enter into an automatic repurchase plan with its designated broker.

• Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

  3/18/2021

  Cipher Pharmaceuticals Inc. (TSX: CPH) today announced its financial and operating results for the three and twelve months ended December 31, 2020

• Cipher Pharmaceuticals Schedules Q4 2020 Earnings Release and Conference Call

  3/10/2021

  Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q4 2020 financial results after the close on Thursday, March 18, 2021.

• Cipher Pharmaceuticals Enters into Co-Promotion Agreement with Verity Pharmaceuticals Inc.

  2/10/2021

   Cipher Pharmaceuticals Inc. (TSX: CPH)today announced it has entered into an exclusive co-promotion agreement with Verity Pharmaceuticals Inc. for the marketing, sales and co-promotion of Brinavess, Aggrastat and Trevyent.

• Cipher Pharmaceuticals Receives Arbitration Award on Trulance

  1/15/2021

  Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it has received an arbitration award in the previously announced dispute between the Company and Bausch Health Ireland ("Bausch Health") relating to the License, Development and Commercialization Agreement (the "Agreement") of Trulance®

• Cipher Pharmaceuticals Reports Third Quarter 2020 Financial Results

  11/13/2020

  Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three and nine months ended September 30, 2020.

• Cipher Pharmaceuticals Schedules Q3 2020 Earnings Release and Conference Call

  11/3/2020

  Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q3 2020 financial results after the close on Thursday, November 12, 2020. 

• Cipher Pharmaceuticals Reports Voting Results for the Election of Directors - Oct 09, 2020

  10/9/2020

  Cipher Pharmaceuticals Inc. announced the voting results for the election of directors at its Annual Meeting of Shareholders held earlier.

• Cipher Pharmaceuticals Announces Normal Course Issuer Bid

  8/12/2020

  Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, a Notice of Intention to Make a Normal Course Issuer Bid (the "Notice").

• Cipher Pharmaceuticals Reports Second Quarter 2020 Financial Results

  8/12/2020

  Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three and six months ended June 30, 2020

• Cipher Pharmaceuticals Schedules Q2 2020 Earnings Release and Conference Call

  7/27/2020

  Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q2 2020 financial results after the close on Wednesday, August 12, 2020. 

• Cipher Pharmaceuticals Appoints New Chief Financial Officer

  7/2/2020

  Cipher Pharmaceuticals Inc. (TSX: CPH) (" Cipher " or " the Company ") is pleased to announce that it has appointed seasoned Financial Executive Scott Langille as its new Chief Financial Officer (CFO), he will succeed Interim CFO Nadine Jutlah . Mr. Langille brings with him an extensive background in corporate and oper

• Cipher Pharmaceuticals Reports First Quarter 2020 Financial Results

  5/7/2020

  Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three months ended March 31, 2020.

• Cipher Pharmaceuticals Schedules Q1 2020 Earnings Release and Conference Call

  4/28/2020

  Cipher Pharmaceuticals Inc. announced it will release its Q1 2020 financial results on Thursday, May 7, 2020. The company will hold a conference call on Friday, May 8, 2020 to discuss the results.

• Cipher Pharmaceuticals Receives Positive Ruling on Binding Arbitration with Upsher-Smith Laboratories

  4/20/2020

  Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the Company has been successful in its binding arbitration with Upsher-Smith Laboratories LLC ("Upsher-Smith").

• Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

  3/25/2020

  Adjusted EBITDA reaches $4.2 million and Net income increases to $2.6 million in the fourth quarter

• Notice of Cipher Pharmaceuticals Q4 2019 Conference Call

  2/20/2020

  OAKVILLE, ON , Feb. 20, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q4 2020 financial results conference call on Thursday, March 26, 2019 . CONFERENCE CALL DETAILS DATE:             Thursday, March 26, 2020 TIME:               8:30 a.m.

• Cipher Pharmaceuticals Provides Update on Absorica Brand Extension Program with Sun Pharmaceutical

  2/6/2020

  Cipher Pharmaceuticals Inc. is pleased to announce that Sun Pharmaceutical Industries Ltd., the Company's U.S. marketing partner for Absorica®, has launched ABSORICA LD™ capsules in the U.S for the management of severe recalcitrant nodular acne in patients 12 years of age and older.

• Cipher Pharmaceuticals Receives Notice of Termination from Bausch

  1/20/2020

  Cipher Pharmaceuticals Inc. announced the Company received a Notice of Termination from Bausch Health in connection with the License, Development and Commercialization Agreement of Trulance®.

• Cipher Pharmaceuticals Reports Third Quarter 2019 Financial Results

  11/7/2019

  Cipher Pharmaceuticals Inc. announced its financial and operating results for the three and nine months ended September 30, 2019. Unless otherwise noted, all figures are in U.S. dollars..